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CASE AND COMMENTARY 
How Should “CRISPRed” Babies Be Monitored Over Their Life Course to 
Promote Health Equity? 
Charis Thompson, PhD 
 
Abstract 
Gene-edited babies who might be born in the future should be monitored 
over the course of their life. These patients’ physical, mental, and social 
health monitoring should be coordinated by clinicians in ways that 
anonymize patients’ data for privacy protection but also allow for 
national and international aggregate evaluations. Transnational 
monitoring efforts should focus on safety and efficacy, social and 
disability justice, what constitutes the standard of care, and how best to 
promote both access to care and social and genomic research and 
innovation. In addition, effective and binding mechanisms for stopping or 
limiting uses of gene editing technology should be developed. 
 
Case 
Dr L and her team are germline editing researchers who are about to begin work with Dr 
M at her university hospital fertility clinic on a germline genome editing pilot protocol 
approved after extensive public comment and review by ethical, safety, disability and 
social justice, and regulatory bodies. Four couples in which both partners are carriers for 
well-studied severe monogenic conditions have given their consent to be involved in the 
clinical trial. 
 
Later in the week, Dr L, Dr M, and the couples will be meeting with Dr C and Dr D, who 
have been designated as the long-term monitoring physicians for physical and mental 
health, respectively, for any children born from this trial. They will also be meeting with 
Dr Q, a bioethics specialist, who will be monitoring the social aspects of follow-up care. 
The purpose of these meetings is to debrief with clinical teams about what kind of 
follow-up monitoring, care, and feedback are appropriate. What should they cover in 
these meetings? How should babies who underwent germline genome editing be 
monitored over the course of their life? 
 
Commentary 
The world’s first known “CRISPRed” babies, Chinese twin girls, were born in October 
2018 after researcher He Jiankui used clustered regularly interspaced short palindromic 
repeat (CRISPR) technology to disable a gene called CCR5 in their genomes so as to 
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render the babies immune to HIV.1 Their father is HIV positive; their mother, the primary 
clinical patient-subject from whom the eggs were extracted and who gestated her twin 
pregnancy after the genome-edited embryos were transferred to her uterus, is HIV 
negative.1 This case brought home to the world the reality of germline genome edited, or 
CRISPRed, babies. Not only have the girls’ genome been altered; if the girls later 
reproduce using their own eggs, their resultant children will inherit the genetic 
modification, which in turn is heritable down subsequent generations. Neither girl had—
nor will any of their genetic descendants have—the option of consenting to this 
modification. To many in China and the West, it was legally questionable, ethically 
problematic, scientifically premature, and clinically unnecessary to take CRISPR clinical at 
the time and for the condition in question.1 The absence of guidelines and mechanisms 
for follow-up care and monitoring of the babies, together with a lack of clear pathways 
by which feedback from such monitoring might be used to improve or halt CRISPR as 
appropriate, highlights the sense of prematurity. This is the right moment to plan ahead 
for comprehensive monitoring and care should there be any future CRISPRed births. 
 
Types of Monitoring 
Physical. Monitoring of CRISPRed children needs to be guided first and foremost by the 
children’s well-being. This purpose should never be displaced by scientific goals. Dr L (the 
genome editing researcher), Dr M (the assisted reproductive technology clinician), and 
the couples should draw up a plan with Dr C (the primary care and coordinating 
physician) for monitoring and, when necessary, mitigating physical effects of the 
modification. It is likely that karyotyping and genome sequencing would be 
recommended. This can be done prenatally or postnatally using biopsy or phlebotomy 
methods commonly available in resource-rich countries during routine prenatal or 
postnatal care. This information would allow Dr L and Dr M to check for genetic 
mosaicism—the incomplete penetration of CRISPR-mediated DNA edits—and to screen 
for unintended off-target effects. Knowing the efficacy and precision of the intervention 
might leave health-related questions unanswered at first because clinical consequences 
of an intended edit and of off-target or incomplete effects will be unknown. The clinical 
justification for collecting this data, however, is to begin to build an evidence base for 
future understanding and care. To reach this goal, there should be a centralized 
mandatory digital reporting facility with international oversight that would collect 
anonymized, privacy-protected data on every CRISPRed child. The data in this repository 
should be tied to and inform ongoing medical care and scientific and social policy. The 
World Medical Association, together with the World Health Organization and its statistics 
repository, the Global Health Observatory,2 would be an ideal locus for this international 
data collation. The United Nations Convention on the Rights of Persons with Disabilities,3 
the Oviedo Convention,4 and reproductive data collection efforts such as the Society for 
Assisted Reproductive Technology Clinic Outcomes Reporting System are examples of 
important potential national and international regulatory and data collection partners. 
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CRISPRed babies and children should be monitored throughout their lives in a routine 
manner, with additional scrutiny for residual effects of the original disease or condition 
for which the technique was employed in the first place and for any physical effects that 
might be linked to the intended edit or to off-target effects. The baseline against which 
their health and well-being should be evaluated should be the health of those receiving 
standard of care for the condition but whose genomes were not edited. Although in 
practice standard of care varies according to local biomedical infrastructure and health 
care access, if CRISPR applications are translated to the clinic, every effort should be 
made to adopt the highest standard of care found anywhere in the world for the 
condition in question. To do so is not just a matter of health equity. Because germline 
modifications are heritable, they have planetary implications and should not be given a 
green light in resource-poor settings simply because it is easier to prove relative efficacy 
and safety against a lower standard of care. 
 
Following childhood, in which the health status and milestones of CRISPRed children are 
measured against those of children receiving standard of care for the condition, 
adolescence would be a period for special physical monitoring and care, particularly 
regarding puberty and the morphology and changes in the DNA of germ cells, which 
could profoundly influence descendants’ reproductive futures. Continuity of prenatal and 
postnatal care and from childhood through adolescence and beyond should be 
prioritized. It is important that women who provide eggs or gestation for CRISPRed 
babies also have their physical health evaluated regularly and that their anonymized 
privacy-protected data be linked to descendants’ data. 
 
Mental health. In a similar manner, Dr L, Dr M, and the couples should draw up a plan 
with Dr D (the mental health practitioner and coordinator) to monitor childhood 
milestones and be ready for early intervention if signs of mental health risks emerge in 
childhood, adolescence, or adulthood. Particular attention should be paid to how the 
child’s understanding of his or her origins might affect the child’s sense of autonomy. As 
a result of disclosure, the child might have difficulty trusting health professionals, which 
might influence how the child interacts in future with the health care community. The 
child might experience anxiety related to having been edited or having an unknown 
biological future. The child’s relations to others living with the condition for which the 
child has been edited also could be complicated. And the impact of widespread public 
antigenome editing sentiment might affect the child’s well-being. 
 
Mental health services would need to be available in case the child came to resent having 
been edited or being targeted by opponents of germline editing. Mindful efforts should 
also be made by the whole care team to pre-emptively involve the child or adolescent in 
directing his or her future and the future of CRISPR, including consideration of options to 
have the edit clinically reversed in some of their own cells (via somatic genome editing) 
or their offspring’s cells (via germline genome editing). Dr D should also monitor family-
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level mental health and arrange treatment, as appropriate, given that a family is likely to 
be a significant unit of well-being for the child. 
 
Social issues. When Dr L, Dr M, and the couples meet with Dr Q (the bioethicist and social 
coordinator), they should discuss which social issues need monitoring and how to begin 
to do that. Crucially, Dr Q will need to liaise with clinicians, insurance companies, and 
policymakers to ensure access to and affordability of treatment and comprehensive 
long-term monitoring of and health care for CRISPRed babies, regardless of ability to 
pay. Other core considerations include ethical questions about monitoring itself, such as 
ensuring consent to participate in monitoring and privacy of data collected during 
monitoring. Questions about monitoring also compass science and industry relations—
for example, whether any children’s data were used for research and innovation. Might 
the family, and later the child, consent to allow use of the child’s anonymized data to 
improve the CRISPR process itself or the care of others with the condition from which 
they might otherwise have suffered? Should they or causes with which they are 
associated benefit from any profit sharing or other returns from a profitable biomedical 
innovation? Plans will also need to be in place to develop international regulatory 
standards. Without shared international standards and regulations, medical tourism by 
and for the wealthy, exploitation of lower-resourced egg donors or surrogates or clinical 
trial participants across borders, and nonevidence-based treatment advertising are all 
likely to develop and to exacerbate inequalities of nation, class, and race.5,6 
 
The families and Dr Q should also discuss how to liaise with health and disability justice 
activists so that information can be passed among all parties about what it means to 
experience removal from the genome of a kind of embodiment shared with others. Given 
that CRISPR risks increasing ableism and diverting resources from the specific condition 
for which it was used, monitoring in this area is essential to protect the reproductive 
futures and rights of those living with the condition and those living with disabilities and 
chronic disease in general. Mechanisms such as regular voluntary meetings among 
CRISPRed persons and their carers and those living with disability should be put in place 
to increase solidarity and decrease stigma and ableism. Together, stakeholders could 
develop standards for unacceptable exacerbation of inequalities, violations of which 
could trigger responses up to and including a return to a moratorium on germline 
genome editing should that be deemed the most socially acceptable path. It would be 
vital to monitor national and international opinion about conditions for which germline 
genome editing is deemed safe, efficacious, and socially and ethically acceptable and to 
put in place mechanisms and instruments to halt temporarily or permanently 
modifications that fail to meet the highest ethical, social, or scientific and clinical 
standards or that turn out to have significant negative effects on particular groups or on 
society as a whole. 
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Finally, Dr L (the genome editing researcher), Dr M (the reproductive technology clinician) 
and the couples should discuss with Dr C (the primary care physician and physical health 
coordinator), Dr D (the mental health practitioner and coordinator), and Dr Q (the 
bioethicist and social coordinator) how to be kept informed about and to participate 
voluntarily in efforts to coordinate collection of data at national and international levels 
on ethical, social, and scientific issues and for purposes of research and innovation. (The 
National Institutes of Health’s All of Us Research Program is an important model for this 
approach.7) It will be clinically important for all CRISPRed children to leverage as much 
robust medical information as possible in making health decisions. Monitoring should 
always be accompanied by mandates to provide care and to address patterns emerging 
from the data. The more that flexible but uniform policies can be developed that respect 
the human rights and dignity of CRISPRed children as well as justice for all others 
affected by CRISPR, the easier it will be to implement scientific and ethical safeguards 
for human germline genome editing. 
 
Conclusion 
In conclusion, with the help of physicians and other coordinators—and for purposes of 
setting scientific, clinical, and social policy on genome editing—national and 
international bodies should at minimum collect data on the following for babies who 
underwent genome editing as embryos: physical and mental well-being over the life 
course; efficacy of the editing process relative to standard of care; unintended effects; 
economic aspects of innovation and access to affordable health care; social effects upon 
the children themselves and their families; and effects upon individuals living with the 
condition and on the wider society as selecting against human variation becomes more 
common. 
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Editor’s Note 
The case to which this commentary is a response was developed by the editorial 
staff. 
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